Showing results (1-10 of 270) with videos related to

Sort By:
Pageof 27
Pharmaceuticals (Basel, Switzerland)|November 20, 2020
Introduction to "Immunotherapies for Multiple Myeloma"Massimo Offidani, Maria Teresa Petrucci
Leukemia & Lymphoma|June 3, 2014
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial dataAntonio Palumbo, Massimo Offidani, Francesca Patriarca, et al.
Cancers|June 10, 2023
Belantamab Mafodotin: From Clinical Trials Data to Real-Life ExperiencesSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Pharmaceuticals (Basel, Switzerland)|December 2, 2020
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma TreatmentSonia Morè, Maria Teresa Petrucci, Laura Corvatta, et al.
Critical Reviews in Oncology/Hematology|February 13, 2022
Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panelCorrado Girmenia, Michele Cavo, Alessandro Corso, et al.
Blood Reviews|January 27, 2019
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendationsCorrado Girmenia, Michele Cavo, Massimo Offidani, et al.
Cancers|April 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple MyelomaKatia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Cancers|August 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Cells|December 18, 2019
The Anti-CD38 Antibody Therapy in Multiple MyelomaMaria Teresa Petrucci, Federico Vozella
Haematologica|July 21, 2022
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panelValerio De Stefano, Alessandra Larocca, Monica Carpenedo, et al.
Pageof 27